Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy.
We evaluated the presence of soluble Fas molecule (sFas) in the cerebrospinal fluids (CSF) and the sera of patients with multiple sclerosis (MS) or human T-lymphotropic virus type I (HTLV-I) associated myelopathy (HAM) using an enzyme-linked immunosorbent assay (ELISA). Patients with multiple sclerosis in the active phase had higher sFas serum levels than control (p < 0.005). In addition, significantly increased serum levels of sFas were found in patients with HAM (p < 0.005). We found a significantly increased CSF levels of sFas in patients with HAM and patients with MS in the active stage (p < 0.005). These results suggest that serum sFas may be related to clinical activity in patients with MS and that Fas may play an important role in the pathogenesis of HAM.
Inoue
A
A
Department of Medicine (Neurology), Shinshu University School of Medicine, Matsumoto, Japan.
Koh
C S
CS
Sakai
T
T
Yamazaki
M
M
Yanagisawa
N
N
Usuku
K
K
Osame
M
M
D000328:Adult; D000368:Aged; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood* / Q000134:cerebrospinal fluid*; D015493:Paraparesis, Tropical Spastic / Q000097:blood* / Q000134:cerebrospinal fluid*; D012995:Solubility; D019014:fas Receptor / Q000032:analysis* / Q000134:cerebrospinal fluid*
D019014:fas Receptor